← Alle Unternehmen
Über das Unternehmen
Traditional early-stage drug discovery depends on screening chemical libraries, a costly and time-consuming process that explores only a tiny fraction of the astronomically large chemical space. Depending on the therapeutic target, these workflows can take several years and cost up to $10M per campaign. We are two PhD students from EPFL, pioneering the field of generative AI for structure-based drug design. We propose to reshape the landscape of early-stage drug discovery by designing novel and target-specific small molecules using our generative AI platform in a matter of seconds. With this technology, we aim to address an unmet market need for fast and cost-efficient design of small molecule drug candidates.